Evidence map›Paper›PMID 31745434›Full record

ArticleSouthern African journal of HIV medicine2019

Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life.

Barbara Laughton, Shalena Naidoo, Els F M T Dobbels, Michael J Boivin, Anita Janse van Rensburg, Richard H Glashoff, Gert U van Zyl, Mariana Kruger, Mark F Cotton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern African journal of HIV medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Barbara LaughtonDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-7260-7723
Shalena NaidooDepartment of Pathology, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-5389-8374
Els F M T DobbelsDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-0597-5451
Michael J BoivinDepartment of Psychiatry, Michigan State University, East Lansing, United States.ORCID https://orcid.org/0000-0002-0097-1777
Anita Janse van RensburgDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-5286-1409
Richard H GlashoffDepartment of Pathology, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-0100-0139
Gert U van ZylNational Laboratory Services, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-3021-5101
Mariana KrugerDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-6838-0180
Mark F CottonDepartment of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-2559-6034

Funding

Latent reservoir characterization and correlations with neurocognitive functioninR01MH105134 · NIMH · STELLENBOSCH UNIVERSITY · PI COTTON, MARK FREDRIC · 2014 to 2018
$3.1M
NIMH NIH HHS R01 MH105134
6 · The paper itself

Abstract

backgroundAntiretroviral therapy (ART) started between 7 and 12 weeks of age improves neurodevelopmental outcomes in HIV-infected (HIV+) infants, but the impact of even earlier initiation is not yet described.

objectivesWe assessed the early neurodevelopment of HIV+ infants who started ART within 21 days of life.

methodParticipants were enrolled from the public sector birth HIV-diagnosis programme. Inclusion criteria included the following: birth weight > 2000 g, infant commencing ART < 6 weeks and no infant cytomegalovirus disease. Antiretroviral therapy included Zidovudine/Lamivudine/Nevirapine for the first 2 weeks, the latter then replaced by Lopinavir/Ritonavir. Once body weight > 3 kg and gestational age > 44 weeks, Abacavir replaced Zidovudine. The Griffiths mental development scales (GMDS) were administered at 10-12 months.

resultsOf 29 infants assessed, 23 (79%) were girls. Mean birth weight was 3002 ± 501 g. Twenty-four mothers (83%) received ART during pregnancy. Seven (24%) infants were diagnosed HIV+ within 48 h of birth. Median [interquartile range] viral load (VL) at diagnosis was 3904 [259-16 922] copies/mL, age starting ART was 6.0 [3-10] days and age at VL suppression was 19.1 [15-36] weeks. At the GMDS assessment, nine (31%) participants had detectable VL and 26 (90%) had World Health Organization (WHO) clinical stage I disease. The GMDS was performed at a mean age of 11.5 ± 0.8 months. Mean quotients were within the average range: Global Griffiths score was 103.6 ± 10.9 and mean quotients on the subscales ranged from lowest 95.9 ± 13.4 for locomotor to highest 112.8 ± 11.3 for hearing-and-language.

conclusionPreliminary findings in this small group suggest that early neurodevelopmental scores are within the normal range in infants with perinatal HIV infection who started ART at a median of 6 days.

Indexed as

antiretroviral therapyHIVinfantsneurodevelopmentpaediatrics

Identifiers

PMID31745434
PMCPMC6852492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.